TRxADE Health (NASDAQ: MEDS), a pharmaceutical exchange platform provider, has entered a binding letter of intent (the “LOI”) to acquire Superlatus Inc., a U.S.-based holding company of food products and distribution capabilities (the “merger”). Upon closing of the merger, Superlatus shareholders will receive 30,821,918 shares of MEDS, each valued at $7.30, and comprised of (i) common shares in an amount representing 19.99% of the total issued and outstanding stock of MEDS after closing, and (ii) the remainder in shares of a new class of MEDS non-voting preferred stock, in each case multiplied by such shareholder’s pro rata percentage ownership. The merger is subject to customary closing conditions including completion of due diligence, delivery of audited financials, approval of a continued listing by Nasdaq and completion of any regulatory approvals.
Upon completion of the merger, TRxADE will pivot its business focus and branding to become an industry-leading processing and forming technologies company that creates the latest generation of delicious, high nutrition, high taste and texture plant-based foods and snacks. “This announcement is a significant milestone for TRxADE shareholders, and we believe that the combined entities will unlock significant value and synergies to be a significant player in the competitive food and snack marketplace,” said Suren Ajjarapu, founder, chairmen/CEO and director of TRxADE. “We believe this strategic transaction that restructures the business to focus on the combined strengths of each organization will provide a competitive advantage in the industry and allow us to gain market share through quality products, customer adoption, and through accretive acquisitions that will create substantial value and returns to our shareholders.”
To view the full press release, visit https://ibn.fm/zn70r
About TRxADE Health Inc.
TRxADE Health is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The company operates the TRxADE drug procurement marketplace serving a total of 14,500+ members nationwide, fostering price transparency and, under the Bonum Health brand, offering patient-centric telehealth services. For more information on TRxADE Health, visit the company’s IR website at investors.trxadegroup.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
